Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H14N5O4P.H2O |
Molecular Weight | 305.2276 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.C[C@H](CN1C=NC2=C(N)N=CN=C12)OCP(O)(O)=O
InChI
InChIKey=PINIEAOMWQJGBW-FYZOBXCZSA-N
InChI=1S/C9H14N5O4P.H2O/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14;/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17);1H2/t6-;/m1./s1
Molecular Formula | C9H14N5O4P |
Molecular Weight | 287.2123 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20439609Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310
CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. CMX157 was designed to mimic lysophosphatidylcholine to take advantage of natural lipid uptake pathways and to achieve high intracellular concentrations of the active antiviral, with the aim of increasing the effectiveness of TFV against wild-type and mutant HIV. CMX157 demonstrated potential to effectively suppress replication of multiNRTI-resistant (MNR) HIV that cannot be treated with any currently available NRTIs, including TDF. It is in phase II clinical trial for HIV infections in USA and phase Ib portion of the phase I/II trial for Hepatitis B in Thailand (PO).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: HIV-1, subtype A 92RW009 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609 |
3.3 nM [EC50] | ||
Target ID: HIV-2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609 |
3.5 nM [EC50] | ||
Target ID: HBV replication Sources: https://www.ncbi.nlm.nih.gov/pubmed/17646420 |
0.49 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02710604
For hepatitis B - 5-100mg tablet
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609
CMX-157 was active against all major subtypes of HIV-1 and HIV-2 in fresh human peripheral blood mononuclear cells (PBMCs) and against all HIV-1 strains evaluated in monocyte-derived macrophages, with 50% effective concentrations (EC(50)s) ranging between 0.20 and 7.2 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:11:25 UTC 2023
by
admin
on
Wed Jul 05 23:11:25 UTC 2023
|
Record UNII |
99YXE507IL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J05AR11
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (FTC/TEN)
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
WHO-ATC |
J05AR18
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
NDF-RT |
N0000175656
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
NCI_THESAURUS |
C97452
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
FDA ORPHAN DRUG |
276209
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (EFV/FTC/TEN)
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
NDF-RT |
N0000175462
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
LIVERTOX |
NBK548917
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
WHO-ATC |
J05AR03
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
NCI_THESAURUS |
C1556
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
||
|
WHO-ATC |
J05AR17
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2592
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
SUB25433
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
C29490
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
Tenofovir
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
99YXE507IL
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
CHEMBL1538
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
CHEMBL483
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
100000089445
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
TENOFOVIR
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
134504
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
63716
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
99YXE507IL
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
C096918
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
DB14126
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
C046573
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
1643601
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
KK-88
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
117466
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | RxNorm | ||
|
206184-49-8
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
21146529
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
63625
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY | |||
|
SUB04721MIG
Created by
admin on Wed Jul 05 23:11:25 UTC 2023 , Edited by admin on Wed Jul 05 23:11:25 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |